drugset / Trial / NCT06925698
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease. The study compares the effectiveness and safety of immunosuppressive therapy alone versus immunosuppressive therapy combined with oral anticoagulation (Rivaroxaban).
Timeline
- Start
- 2025-04-30
- Primary completion
- 2027-04-01
- Completion
- 2028-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rivaroxaban | Other / unclassified | 20 mg | Oral |
| Comparator | Azathioprine | Small molecule | 2.5 mg/kg | Oral |
| Comparator | Methylprednisolone | Other / unclassified | 0.5 mg/kg | Oral |